Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
DNA Ginkgo Bioworks Holdings, Inc.
Developers are navigating confusing gaps between expectation and reality. So are the rest of us. Depending who you ask, AI-powered coding is either giving software developers an unprecedented ...
Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...
Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...
It's not just about asking a chatbot to spin up a few lines. It can look at files within your code repository, analyze them, and understand them. It can search the internet for information, and access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback